Closed

Kilitch Drugs India Limited Rights Issue 2026

BSE, NSE
Issue Price ₹357 Face Value: ₹10.00
Current Market Price N/A BSE / NSE secondary market
Rights Ratio (RE) 2:23 2 share for every 23 held
Total Issue Size TBA Capital being raised
Record Date 15 Jul 2025 Eligibility cut-off date
INTERACTIVE ESTIMATOR

Kilitch Drugs India Limited Rights Entitlement & Capital Calculator

Calculate your eligible rights share allocation and total application cost based on the official 2:23 ratio at ₹357.00 per share.

Ratio: 2:23
Shares
Quick select:
Enter your holdings as on 15 Jul to recalculate.
Entitlement Calculation Terms
Rights Price ₹357.00
Entitlement Ratio 2:23
Record Date 15 Jul
For every 23 shares in your demat, you are entitled to apply for 2 rights shares.
ALLOTMENT ESTIMATE 2:23 Entitlement
Eligible Rights Shares -- Based on 2:23 ratio
Total Investment Required -- @ ₹357.00/share
Apply online via Net Banking ASBA. Amount remains blocked in your bank account until allotment.
MARKET QUOTE & TECHNICAL TREND

Kilitch Drugs India Limited Stock Quote & Price Trend

NSE: KILITCH
₹236.95 ▲ ₹6.83 (2.97%)
CMP vs Issue Price: Issue Price: ₹357.00
Period High ₹260.70 Highest in range
Period Low ₹158.10 Lowest in range
Rights Issue Price ₹357.00 Per equity share
STRUCTURE & SPECIFICATIONS

Issue Overview & Specifications

Company Name Kilitch Drugs India Limited
Rights Entitlement (Ratio)
2:23 (2 share for every 23 held)
Issue Price ₹357 per equity share
Face Value ₹10.00 per share
Total Issue Size TBA
Number of Shares Offered TBA
Listing Exchanges BSE, NSE
Registrar to the Issue Link Intime India Private Limited
SCHEDULE & DATES

Kilitch Drugs India Limited Rights Issue Timetable

1
Record Date 15 Jul 2025

Cut-off date determining eligible shareholders entitled to receive Rights Entitlements (RE).

2
Issue Opens Date 23 Jul 2025

Bidding opens. Eligible investors can apply online via Net Banking ASBA.

3
Last Date for On-Market Renunciation TBA

Last trading day to sell or transfer your Rights Entitlements (RE) on the stock exchange.

4
Issue Closes Date TBA

Final deadline to submit your ASBA rights issue application with blocked funds.

5
Basis of Allotment 22 Aug 2025

Finalization of allotment by the registrar and company.

6
Listing & Credit of Shares 26 Aug 2025

Allotted rights shares are credited to demat accounts and commence trading on BSE/NSE.

STEP-BY-STEP PROCESS

How to Apply for Kilitch Drugs India Limited Rights Issue

1
Check Rights Entitlement (RE) in Demat

Once the record date passes, Rights Entitlements (RE) will be credited directly to your demat account under temporary ISIN COMPANY-RE.

2
Decide: Apply, Renounce (Sell), or Apply for Additional Shares

You can apply for your exact entitlement, apply for additional shares over and above your entitlement, or sell your RE shares in the stock market before the renunciation deadline.

3
Apply via Net Banking ASBA

Log in to your bank's net banking portal (HDFC, ICICI, SBI, Axis, Kotak, etc.). Go to IPO / Rights Issue section, select Kilitch Drugs India Limited Rights Issue, enter your Demat account (BOID/DPID) details, and submit.

QUESTIONS & ANSWERS

Kilitch Drugs India Limited Rights Issue FAQs

Kilitch Drugs India Limited Rights Issue offers equity shares at ₹357.00 per share with an entitlement ratio of 2:23 (Face value ₹10.00).
The official record date for Kilitch Drugs India Limited Rights Issue is 15 Jul 2025. Shareholders holding shares in demat on this date are entitled to Rights Entitlements (RE).
Rights Entitlements (RE) are credited directly to eligible shareholders' demat accounts under temporary ISIN COMPANY-RE. You can either apply for shares using REs or renounce (sell) them in the stock market during the trading window.
Investors can apply online via Net Banking through ASBA (Applications Supported by Blocked Amount) by selecting Kilitch Drugs India Limited Rights Issue in the IPO/Rights section and entering Demat account (BOID/DPID) details.
If you do not apply or sell your Rights Entitlements on the stock exchange before the last date of renunciation, the REs will expire and lapse worthless, resulting in shareholding dilution.
সম্পর্কিত বিষয়সমূহ